Solid preparation and manufacturing method thereof

A solid formulation with Compound I, starch, and hydroxypropylcellulose or hypromellose stabilizes Compound I and enhances disintegration, addressing stability and decomposition issues in solid preparations.

JP2024169553AActive Publication Date: 2024-12-05NIPPON SHINYAKU CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2024160556
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-04-10
Filing Date
2024-09-18
Publication Date
2024-12-05
Estimated Expiration
2041-04-09

AI Technical Summary

Technical Problem

Solid preparations containing Compound I, used for their medicinal properties, face challenges in maintaining stability while improving disintegration properties, especially when the binder is omitted, leading to increased decomposition and related substance generation.

Method used

A solid formulation comprising Compound I, starch, and a binder selected from hydroxypropylcellulose or hypromellose, with specific ratios and methods of granulation, including wet granulation, to stabilize Compound I and enhance disintegration properties.

Benefits of technology

The formulation effectively suppresses the decomposition of Compound I, maintaining its stability and improving disintegration properties, ensuring effective medicinal delivery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024169553000001
    Figure 2024169553000001
  • Figure 2024169553000002
    Figure 2024169553000002
  • Figure 2024169553000003
    Figure 2024169553000003
Patent Text Reader

Abstract

To provide a solid preparation containing 2-{4-[N-(5,6-diphenyl pyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide (Compound I).SOLUTION: A solid preparation contains a granulated material containing (A) a compound I, (B) starch, and (C) at least one binder selected from a group consisting of hydroxypropylcellulose and hypromellose. In the granulated material 100 mass%, proportions of the components (B) and (C) are 36 pts.mass or more and 0.5-4 pts.mass, respectively. The granulated material is prepared by wet granulation using the component (C) in an aqueous solution state.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to a solid formulation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide (generic name "Selexipag", hereinafter also referred to as "Compound I" in this specification). In a preferred embodiment, the present disclosure relates to a solid preparation in which the decomposition of Compound I is suppressed, the compound is stably contained, and the solid preparation has good disintegrability. [Background technology]

[0002] The following structural formula: [ka] Compound I represented by the formula (I) has an excellent prostaglandin I2 (also known as PGI2) receptor agonist effect, and is known to exhibit various pharmacological effects such as platelet aggregation inhibitory effect, vasodilatory effect, bronchial smooth muscle dilating effect, lipid deposition inhibitory effect, and leukocyte activation inhibitory effect (Patent Documents 1 to 7).

[0003] Patent Document 3 discloses a tablet containing Compound I and D-mannitol. In this tablet, D-mannitol is used as an excipient, and the specific surface area of ​​D-mannitol is 1.0 m 2 The following is formed. This makes it possible to inhibit the decomposition of Compound I in tablets containing D-mannitol. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication No. 2002 / 088084 [Patent Document 2] International Publication No. 2009 / 157398 [Patent Document 3] International Publication No. 2017 / 098998

Patent document 4

Patent document 5

Patent document 6

Patent document 7

Non-licensed literature

[0005] [Non-licensed document 1] Hepatology,2007,Vol.45,No.1,p159-169. [Non-licensed document 2] Folia Pharmacologica Japonica, Vol.117, No.2, p.123-130, 2001, Abstract. [Non-licensed document 3] International Angiology,29,Suppl.1 to No.2,p.49-54,2010.

Non-licensed Document 4

Non-licensed Document 5

Non-licensed Document 6

Non-licensed Document 7

Non-licensed Document 8

Non-licensed literature 9

Non-licensed literature 10

[0006] In recent years, in order to further improve the convenience of administration for children, the elderly, and patients with difficulty in swallowing, solid preparations with good disintegration properties are desired. The present inventors assumed that the binder in the solid preparation would reduce disintegration properties, and conducted an investigation by omitting the binder from the solid preparation containing compound I. As a result, although the disintegration properties of the solid preparation were improved, the decomposition of compound I in the solid preparation proceeded, and related substances were generated, resulting in a decrease in the content of compound I. In other words, it was found that omitting the binder from the solid preparation containing compound I improved disintegration properties, while decreasing the stability of compound I in the solid preparation.

[0007] An object of the present disclosure is to provide a solid formulation containing Compound I, and a method for producing the same. Another object of the present disclosure is to provide a solid formulation in which the stability of Compound I in the solid formulation is suppressed from decreasing while improving disintegrability, and a method for producing the same. [Means for solving the problem]

[0008] Means for Solving the Problems The present inventors have conducted intensive research to solve the above problems, and as a result have found that by using, as granulation components of a solid formulation, starch together with Compound I, and at least one binder selected from the group consisting of hydroxypropyl cellulose and hypromellose in a specific ratio, the solid formulation exhibits good disintegrability while suppressing decomposition of Compound I, and Compound I is stably retained. The present disclosure was completed based on these findings and through further research. Some embodiments of the present disclosure include the following.

[0009] (Solid preparations) Item 1. (A) 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide, (B) starch; (C) at least one binder selected from the group consisting of hydroxypropyl cellulose and hypromellose; A solid formulation comprising a granule comprising: The ratio of the (B) component per 100 parts by mass of the granules is 36 parts by mass or more, The ratio of the component (C) per 100 parts by mass of the granules is 0.5 to 4 parts by mass, The granules are wet granulated using component (C) in the form of an aqueous solution. The solid formulation. Item 2. (A) 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide, (B) starch; (C) at least one binder selected from the group consisting of hydroxypropyl cellulose and hypromellose; (D) at least one excipient selected from the group consisting of sugar alcohols and sugars; (F) Lubricant and A solid formulation comprising: The solid preparation is composed of at least a granule and an excipient other than the granule, The granule contains at least the components (A), (B), (C) and (D), The external additive for the granules contains at least the component (F), At least one of the granules and the external additives to the granules contains (E) at least one disintegrant selected from the group consisting of carmellose, carmellose calcium, carmellose sodium, croscarmellose sodium, crystalline cellulose, low-substituted hydroxypropyl cellulose, and crospovidone; The ratio of the (B) component per 100 parts by mass of the granules is 36 parts by mass or more, The ratio of the component (C) per 100 parts by mass of the granules is 0.5 to 4 parts by mass. The solid formulation. Item 3. The solid formulation according to Item 2, wherein the granules are obtained by wet granulation using component (C) in the form of an aqueous solution. Item 4. The solid formulation according to Item 2 or 3, wherein the (D) excipient is D-mannitol. Item 5. The solid formulation according to any one of Items 2 to 4, wherein the mass ratio of the component (B) to the component (D) in the granules is 2 parts by mass or more when the total of the components (B) and (D) is 10 parts by mass. Item 6. The solid formulation according to any one of Items 2 to 5, wherein the granules further contain (E) a disintegrant. Item 7. The solid preparation according to any one of claims 2 to 6, which has a tablet shape and is surface-coated with a coating agent. Item 8. The solid preparation according to any one of Items 1 to 7, which is for treating a symptom associated with at least one disease selected from the group consisting of diabetic neuropathy, diabetic gangrene, peripheral circulatory disorder, chronic arterial occlusion, intermittent claudication, scleroderma, thrombosis, pulmonary hypertension, myocardial infarction, angina pectoris, glomerulonephritis, diabetic nephropathy, chronic renal failure, bronchial asthma, interstitial pneumonia (pulmonary fibrosis), chronic obstructive pulmonary disease, tubulointerstitial nephritis, inflammatory bowel disease, and spinal canal stenosis.

[0010] (I) Selexipag-containing solid formulation (I-1) (A) 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide (Compound I), (B) starch; (C) at least one binder selected from the group consisting of hydroxypropyl cellulose (hereinafter also referred to as "HPC") and hypromellose A solid formulation comprising a granule comprising: The content of the component (B) per 100 parts by mass of the granules is 20 parts by mass or more (excluding 30.2 to 30.4 parts by mass), A solid preparation, wherein the content of the component (C) per 100 parts by mass of granules is 4 parts by mass or less. (I-2) The solid formulation according to (I-1), wherein the granule is a wet granule. (I-3) A solid formulation according to (I-1) or (I-2), in which the content of component (B) per 100 parts by mass of the granules is greater than 30.4 parts by mass. (I-4) The solid formulation according to any one of (I-1) to (I-3), wherein the component (C) is HPC and the content of the HPC is 1 to 4 parts by mass per 100 parts by mass of the granules. (I-5) The solid formulation according to any one of (I-1) to (I-3), wherein the component (C) is HPC and the content of the HPC is 2 to 3 parts by mass per 100 parts by mass of the granules. (I-6) The solid formulation according to any one of (I-1) to (I-3), wherein the component (C) is hypromellose, and the content of the hypromellose is 1 to 4 parts by mass per 100 parts by mass of the granules. (I-7) The solid preparation according to any one of (I-1) to (I-6), wherein the granules further contain (D) an excipient other than starch. (I-8) The solid formulation according to (I-7), wherein the (D) excipient is D-mannitol. (I-9) The solid formulation according to (I-7) or (I-8), wherein the mass ratio of the (B) component to the (D) component excluding starch in the granules is (B) component:(D) component excluding starch)=10:0 to 2:8. (I-10) The solid preparation according to any one of (I-1) to (I-9), wherein the granules further contain (E) a disintegrant. (I-11) The solid preparation according to any one of (I-1) to (I-10), which has a tablet shape. (I-12) A solid preparation according to any one of (I-1) to (I-10), which has a tablet shape and is surface-coated with a coating agent. (I-13) The solid preparation according to any one of (I-1) to (I-12), comprising the granules and, as an external additive to the granules, at least one selected from the group consisting of (D) an excipient, (E) a disintegrant, and (F) a lubricant. (I-14) The solid preparation according to any one of (I-1) to (I-13), wherein the content of the component (A) is less than 0.2 mg. (I-15) The solid formulation according to any one of (I-1) to (I-14), which is a tablet having a total mass of 30 mg or less. (I-16) The solid preparation according to any one of (I-1) to (I-15), which is a tablet having a circular planar shape with a diameter of 4 mm or less. (I-17) The solid formulation according to any one of (I-1) to (I-16), which is for treating symptoms associated with at least one disease selected from the group consisting of diabetic neuropathy, diabetic gangrene, peripheral circulatory disorder, chronic arterial occlusion, intermittent claudication, scleroderma, thrombosis, pulmonary hypertension, myocardial infarction, angina pectoris, glomerulonephritis, diabetic nephropathy, chronic renal failure, bronchial asthma, interstitial pneumonia (pulmonary fibrosis), chronic obstructive pulmonary disease, tubulointerstitial nephritis, inflammatory bowel disease, and spinal canal stenosis. (I-18) The solid formulation according to (I-17), which is for treating pulmonary hypertension. (I-19) A solid formulation according to (I-17) for treating peripheral circulatory disorders. (I-20) A solid formulation according to (I-17) for treating chronic arterial occlusion. (I-21) A solid formulation according to (I-17) for treating intermittent claudication. (I-22) A solid formulation according to (I-17) for treating symptoms associated with spinal canal stenosis. (I-23) A solid formulation according to (I-17) for treating pulmonary fibrosis. (I-24) A solid formulation according to (I-17) for treating scleroderma. (I-25) A solid formulation according to (I-17) for treating chronic renal failure. (I-26) A solid formulation according to (I-17) for treating tubulointerstitial nephritis.

[0011] (II) Manufacturing method of a solid preparation containing selexipag (II-1) A method for producing a solid preparation comprising a granule containing (A) 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide (Compound I), (B) starch, and (C) at least one binder selected from the group consisting of HPC and hypromellose, (1) preparing a powder mixture of the components (A) and (B); (2) adding a solution containing the component (C) to the powder mixture and granulating the mixture to obtain a granulated product; Including, In the step (1), the powder mixture is prepared so that the content of the component (B) per 100 parts by mass of the granules is 20 parts by mass or more (excluding 30.2 to 30.4 parts by mass), and In the step (2), the solution containing the component (C) is added so that the content of the component (C) per 100 parts by mass of the granules is 4 parts by mass or less. Manufacturing method. (II-2) The production method according to (II-1), wherein the content of the component (B) is greater than 30.4 parts by mass per 100 parts by mass of the granules. (II-3) The production method according to (II-1) or (II-2), wherein the solution containing the component (C) contains the component (C) in a proportion of 1 to 10 mass %. (II-4) The method according to any one of (II-1) to (II-3), wherein the component (C) is HPC, and the method comprises a step of spraying an HPC-containing solution onto a powder mixture of the components (A) and (B) so that the content of HPC per 100 parts by mass of the granules is 1 to 4 parts by mass, preferably 2 to 3 parts by mass. (II-5) A method for producing a powder mixture of components (A) and (B) comprising spraying a hypromellose-containing solution onto the powder mixture of components (A) and (B) so that the hypromellose content per 100 parts by mass of granules is 1 to 4 parts by mass, comprising the steps of: (C) component being hypromellose; (II-6) The method according to (II-5), wherein the viscosity of an aqueous solution containing 2% by mass of hypromellose at 20°C ± 1°C is less than 4 mPa s when measured under the conditions of Method 1 of the Viscosity Measurement Method (capillary viscometer method) of the Japanese Pharmacopoeia, Seventeenth Edition. (II-7) The method according to any one of (II-1) to (II-6), wherein the powder mixture further contains (D) an excipient other than starch. (II-8) The method according to (II-7), wherein the (D) is D-mannitol.(II-9) The method according to (II-7) or (II-8), wherein the mass ratio of the (B) component to the (D) component excluding starch in the powder mixture is (B) component:(D) component excluding starch)=10:0 to 2:8. (II-10) The production method according to any one of (II-1) to (II-9), wherein the powder mixture further contains (E) a disintegrant. (II-11) The method according to any one of (II-1) to (II-10), further comprising, after the (2) granulation step and, if necessary, after the (3) sizing step, (4) a step of adding at least one external additive selected from the group consisting of (D) an excipient, (E) a disintegrant, and (F) a lubricant (post-addition step). (II-12) The production method according to (II-11), further comprising a compression molding step (5) after the post-addition step (4). (II-13) The production method according to (II-12), further comprising a step of coating the compression molded product obtained in the compression molding step (5). (II-14) The method according to any one of (II-1) to (II-13), wherein the solid preparation is a preparation for treating a symptom associated with at least one disease selected from the group consisting of diabetic neuropathy, diabetic gangrene, peripheral circulatory disorder, chronic arterial occlusion, intermittent claudication, scleroderma, thrombosis, pulmonary hypertension, myocardial infarction, angina pectoris, glomerulonephritis, diabetic nephropathy, chronic renal failure, bronchial asthma, interstitial pneumonia (pulmonary fibrosis), chronic obstructive pulmonary disease, tubulointerstitial nephritis, inflammatory bowel disease, and spinal canal stenosis.

[0012] (III) Method for inhibiting decomposition of selexipag in a solid preparation containing selexipag (III-1) A method for suppressing decomposition of the component (a) in a solid preparation containing a granule containing (a) 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide (Compound I), (b) starch, and (c) a binder, comprising: The above method, wherein at least one compound selected from the group consisting of HPC and hypromellose is used as component (c). (III-2) The method according to (III-1), wherein the blending amount of the component (c) is 1 to 4 parts by mass per 100 parts by mass of the granules. (III-3) The method according to (III-1) or (III-2), further comprising a step of spraying an aqueous solution containing the component (c) onto a powder mixture of the components (a) and (b) to wet granulate the mixture. (III-4) The method according to (III-3), wherein the component (c) is hypromellose, and the viscosity of an aqueous solution containing 2% by mass of hypromellose at 20°C ± 1°C is less than 4 mPa s when measured under the conditions of Viscosity Measurement Method 1 of the Japanese Pharmacopoeia, Seventeenth Edition. (III-5) The method according to any one of (III-1) to (III-4), wherein the granules may further contain D-mannitol as an excipient (d) other than starch, and the mass ratio of the component (b) to the component (d) other than starch is (component (b) : (d) component other than starch) = 10:0 to 2:8. (III-6) The method according to any one of (III-1) to (III-5), wherein the content of the component (a) in the solid preparation is less than 0.2 mg. (III-7) The method according to any one of (III-1) to (III-6), wherein the solid preparation is a preparation for treating a symptom associated with at least one disease selected from the group consisting of diabetic neuropathy, diabetic gangrene, peripheral circulatory disorder, chronic arterial occlusion, intermittent claudication, scleroderma, thrombosis, pulmonary hypertension, myocardial infarction, angina pectoris, glomerulonephritis, diabetic nephropathy, chronic renal failure, bronchial asthma, interstitial pneumonia (pulmonary fibrosis), chronic obstructive pulmonary disease, tubulointerstitial nephritis, inflammatory bowel disease, and spinal canal stenosis.

[0013] (IV) Method for inhibiting the decomposition of selexipag and improving disintegrability in a solid preparation containing selexipag (IV-1) A method for suppressing decomposition of component (a) and improving disintegrability in a solid preparation containing a granule containing (a) 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide (compound I), (b) starch, and (c) a binder, comprising: The above method, wherein at least one compound selected from the group consisting of HPC and hypromellose is used as component (c). (IV-2) The method according to (IV-1), wherein the blending amount of the component (c) is 1 to 4 parts by mass per 100 parts by mass of the granules. (IV-3) The method according to (IV-1) or (IV-2), wherein the component (c) is HPC and the amount of HPC blended is 2 to 3 parts by mass per 100 parts by mass of the granules. (IV-4) The method according to (IV-1) or (IV-2), wherein the component (c) is hypromellose and is blended in an amount of 1 part by mass per 100 parts by mass of the granules. (IV-5) The method described in (IV-4), wherein the component (c) is hypromellose, and the viscosity of an aqueous solution containing 2% by mass of hypromellose at 20°C ± 1°C is less than 4 mPa s when measured under the conditions of Viscosity Measurement Method 1 of the Japanese Pharmacopoeia, Seventeenth Edition. (IV-6) The method according to any one of (IV-1) to (IV-5), wherein the granules may further contain D-mannitol as an excipient (d) other than starch, and the mass ratio of the component (b) to the component (d) other than starch is (component (b) : (d) component other than starch) = 10:0 to 2:8. (IV-7) The method according to any one of (IV-1) to (IV-6), wherein the content of the component (a) in the solid preparation is less than 0.2 mg. (IV-8) The method according to any one of (IV-1) to (IV-7), wherein the solid preparation is a tablet having a circular planar shape with a diameter of 4 mm or less. (IV-9) The method according to any one of (IV-1) to (IV-8), wherein the solid preparation is a preparation for treating a symptom associated with at least one disease selected from the group consisting of diabetic neuropathy, diabetic gangrene, peripheral circulatory disorder, chronic arterial occlusion, intermittent claudication, scleroderma, thrombosis, pulmonary hypertension, myocardial infarction, angina pectoris, glomerulonephritis, diabetic nephropathy, chronic renal failure, bronchial asthma, interstitial pneumonia (pulmonary fibrosis), chronic obstructive pulmonary disease, tubulointerstitial nephritis, inflammatory bowel disease, and spinal canal stenosis. Effect of the Invention

[0014] According to the present invention, it is possible to provide a solid preparation that can suppress a decrease in the stability of Compound I in a solid preparation while improving disintegrability, and a method for producing the same. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] (I) Selexipag-containing solid formulation The solid formulation of the present disclosure (hereinafter, sometimes simply referred to as "the solid formulation") is a solid formulation comprising a granule containing at least one binder selected from the group consisting of (A) compound I, (B) starch, (C) HPC, and hypromellose, wherein the content of the (B) component per 100 parts by mass of the granule is 20 parts by mass or more (excluding 30.2 to 30.4 parts by mass), and the content of the (C) component per 100 parts by mass of the granule is 4 parts by mass or less.

[0016] In the present disclosure, unless otherwise specified, the term "solid preparation" refers to a solid preparation of a certain shape for oral administration, which includes, in addition to ordinary tablets, orally disintegrating tablets, chewable tablets, troche tablets, sublingual tablets, effervescent tablets, dispersible tablets, dissolving tablets, sustained-release tablets (these may be collectively referred to as "tablets"), granules, and capsules. Tablets are preferred, and ordinary tablets are more preferred. In addition, the solid preparations covered by the present disclosure include single-layer tablets having a single layer structure and multi-layer tablets having a multi-layer structure of two or more layers. Single-layer tablets are preferred. In addition, the solid preparations of the present disclosure include uncoated plain tablets (plain tablets), sugar-coated tablets, gelatin-coated tablets, and film-coated tablets (including enteric-coated tablets and gastrosoluble tablets) (these are also collectively referred to as "coated tablets" in contrast to plain tablets). The planar shape of the solid preparation is not particularly limited, and may be various shapes such as circular, elliptical, caplet-shaped, and donut-shaped. The solid preparation contains the above granulated material (core granules) and an additive other than the granulated material that is added to the above granulated material.

[0017] Each component constituting the solid preparation of the present disclosure will be described below.

[0018] (A) Compound I Compound I can be prepared, for example, according to the method described in Patent Document 1 or 2, and the following three crystal forms are known. The relevant descriptions in these patent documents are incorporated herein by reference. (1) A type I crystal of Compound I, whose powder X-ray diffraction pattern is obtained using Cu Kα radiation (λ=1.54 Å) and which shows diffraction peaks at the following diffraction angles 2θ: 9.4 degrees, 9.8 degrees, 17.2 degrees, and 19.4 degrees in the powder X-ray diffraction spectrum of Compound I. (2) A form II crystal of compound I, the powder X-ray diffraction pattern of which is obtained using Cu Kα radiation (λ=1.54 Å) and which shows diffraction peaks at the following diffraction angles 2θ: 9.0 degrees, 12.9 degrees, 20.7 degrees, and 22.6 degrees in the powder X-ray diffraction spectrum of compound I. (3) A type III crystal of Compound I, the powder X-ray diffraction pattern of which is obtained using Cu Kα radiation (λ=1.54 Å) and which shows diffraction peaks at the following diffraction angles 2θ: 9.3 degrees, 9.7 degrees, 16.8 degrees, 20.6 degrees, and 23.5 degrees in the powder X-ray diffraction spectrum of Compound I.

[0019] Compound I that can be used in the present solid preparation may be any of the above crystals, or may be a mixture of these crystals or an amorphous system. Among them, type I crystal is preferred.

[0020] In addition, when the content ratio of compound I is converted into the content per 100 parts by mass of the granules contained in the solid formulation, it can be in the range of 0.1 to 70 parts by mass, but is not limited thereto. When the solid formulation is a tablet produced by the production method A described below, the content ratio of compound I in 100 parts by mass of the granules is preferably 0.1 to 12 parts by mass, more preferably 0.1 to 2 parts by mass. When the solid formulation is a tablet produced by the production method B described below, the content ratio of compound I in 100 parts by mass of the granules is preferably 0.1 to 40 parts by mass, more preferably 0.1 to 5 parts by mass.

[0021] The proportion of compound I contained in the solid preparation is not limited, and can be selected from the range of 0.1 to 25% by mass, more preferably 0.1 to 12% by mass, and even more preferably 0.1 to 2% by mass, per 100% by mass of the total amount of the solid preparation. Here, the "total amount of the solid preparation" means the "total amount of uncoated tablets" when the solid preparation is a tablet (hereinafter the same).

[0022] (B) Starch In the present disclosure, the starch (hereinafter also simply referred to as "component (B)") may be any starch that can be used as a pharmaceutical additive in the production of a solid preparation, and examples of the natural starch include corn starch, potato starch, rice starch, and wheat starch, and examples of the modified starch include hydroxypropyl starch, dextrin, maltodextrin, pregelatinized starch, and partially pregelatinized starch. The starch is preferably used as an excipient, and preferably includes corn starch. The form of the starch is not limited and includes powder and granules, and is preferably powder.

[0023] The content of the (B) component, calculated as the content per 100 parts by mass of the granules contained in the present solid preparation, can be 20 parts by mass or more (excluding 30.2 to 30.4 parts by mass). When the present solid preparation is a tablet produced by the production method A, the content of the (B) component in 100 parts by mass of the granules is preferably more than 30.4 parts by mass, more preferably more than 36 parts by mass. When the present solid preparation is a tablet produced by the production method B, the content of the (B) component in 100 parts by mass of the granules is preferably 20 to 40 parts by mass (excluding 30.2 to 30.4 parts by mass), more preferably 30.5 to 40 parts by mass, and even more preferably 36 to 40 parts by mass.

[0024] The proportion of component (B) contained in the present solid preparation is not limited and is 20% by mass or more, preferably 30 to 40% by mass, and more preferably 36 to 40% by mass, per 100% by mass of the total amount of the solid preparation.

[0025] In addition, when the granules (core granules) contain a (D) excipient other than starch as described below as a component other than the (A) to (C) components, the blending ratio (mass ratio) of the (B) component to the (D) excipient other than starch can be selected, without limitation, from the range of preferably (B) component: (D) excipient other than starch = 10:0 to 2:8. More preferably, it is 8:2 to 3:7, and particularly preferably 7:3 to 3:7. Here, a suitable example of the (D) excipient other than starch is D-mannitol.

[0026] (C) Binder In the present disclosure, the binder is at least one selected from the group consisting of hydroxypropyl cellulose (HPC) and hypromellose (hereinafter, also simply referred to as "component (C)"). The component (C) may be any component that can be used as a binder in the production of a solid preparation as a pharmaceutical additive. The component (C) may be used alone or in combination of two or more types.

[0027] HPC commercially available as a pharmaceutical additive includes HPC having a molecular weight (GPS) in the range of 40,000 to 2,500,000 (viscosity when prepared in a 2% aqueous solution at 20°C: 2 to 6,000 mPa·s) (for example, NISSO HPCSSL, SL, L, M, H, VH, etc.; all manufactured by Nippon Soda Co., Ltd.). In the present disclosure, preferably, HPC having a molecular weight (GPS) in the range of 40,000 to 140,000 (said viscosity: 2 to 10 mPa·s); more preferably, HPC having a molecular weight (GPS) in the range of 40,000 to 100,000 (said viscosity: 2 to 5.9 mPa·s); particularly preferably, HPC having a molecular weight (GPS) of 40,000 (said viscosity: 2 to 2.9 mPa·s) can be used.

[0028] Hypromellose commercially available as a pharmaceutical additive includes hypromellose having a degree of substitution of 28.0 to 30.0% for methoxy groups and 7.0 to 12.0% for hydroxypropoxy groups, and having a viscosity in the range of 2.5 to 17.5 mPa·s when prepared in a 2% aqueous solution at 20°C (e.g., Hypromellose TC-5 (registered trademark) [types: E, M, R, S]; all manufactured by Shin-Etsu Chemical Co., Ltd.). In the present disclosure, preferably, hypromellose having a viscosity in the range of 2.5 to 7.0 mPa·s; more preferably, hypromellose having a viscosity in the range of 2.5 to 5.1 mPa·s; and particularly preferably, hypromellose having a viscosity in the range of 2.5 to 3.5 mPa·s can be used. Other commercially available hypromelloses as pharmaceutical additives include those having a degree of substitution of methoxy groups of 19.0 to 24.0% and a degree of substitution of hydroxypropoxy groups of 4.0 to 12.0%, and having a viscosity in the range of 3.2 to 4.8 mPa s when prepared in a 2% aqueous solution at 20°C (e.g., hypromellose SB-4); and those having a degree of substitution of methoxy groups of 27.0 to 30.0% and a degree of substitution of hydroxypropoxy groups of 4.0 to 7.5% (e.g., hypromellose 65SH) (both manufactured by Shin-Etsu Chemical Co., Ltd.).

[0029] The content of component (C) is 4 parts by mass or less when converted into the content per 100 parts by mass of the granules contained in the solid preparation.

[0030] When the solid preparation is a tablet produced by manufacturing method A, the proportion of component (C) in 100 parts by mass of the granules is not limited, but examples of the proportion include 0.5 to 4 parts by mass, preferably 0.5 to 3.5 parts by mass, for HPC and 0.5 to 4 parts by mass, preferably 0.5 to 3.5 parts by mass for hypromellose.

[0031] When the solid preparation is a tablet produced by manufacturing method B, the ratio of component (C) in 100 parts by mass of the granules is, for HPC, 0.5 to 4 parts by mass, preferably 0.5 to 3.5 parts by mass; and for hypromellose, 0.5 to 4 parts by mass, preferably 0.5 to 3.5 parts by mass.

[0032] In any of the manufacturing methods, when HPC and hypromellose are used in combination as component (C), it is preferable to appropriately adjust the total amount of both to 4 parts by mass or less.

[0033] The component (C) is used in a state dissolved in water. Specifically, a granulated product containing at least the components (A) to (C) can be prepared by adding the component (C) in an aqueous solution state to a powder mixture containing the components (A) and (B) described above and granulating the mixture (wet granulation method). The concentration of the aqueous solution of the component (C) used is not limited, but can be appropriately selected from the range of 0.5 to 20% by mass. It is preferably 0.5 to 10% by mass. As shown in Experimental Example 5 described later, when the content of the component (C) in 100 parts by mass of the granulated product is as low as 1.1 parts by mass or less, the content of the component (C) in the aqueous solution used for wet granulation can be adjusted to a low concentration of 0.5 to 5% by mass, preferably 1 to 5% by mass, to enhance the decomposition suppression effect (stabilization effect) of the compound I.

[0034] (Other pharmaceutical excipients) The present solid preparation may contain other pharmaceutical additives as optional components, to the extent that the effects described herein are not impaired. Examples of such pharmaceutical additives preferably include (D) excipients other than starch, (E) disintegrants, and (F) lubricants. Other examples of pharmaceutical additives that can be added optionally include solubilizers, fluidizing agents, wetting agents, adsorbents, surfactants, pH adjusters, plasticizers, antioxidants, preservatives, colorants, flavoring agents, sweeteners, flavoring agents, etc. These pharmaceutical additives can be used alone or in any combination of two or more.

[0035] (D) Excipients Examples of the (D) excipient, in addition to the starch mentioned above as the (B) component, include, but are not limited to, sugar alcohols (e.g., D-mannitol, erythritol, D-sorbitol, maltitol, isomalt, lactitol, xylitol, and powdered reduced maltose syrup, etc.), sugars (e.g., lactose, glucose, fructose, sucrose, etc.), crystalline cellulose, powdered cellulose, β-cyclodextrin, carmellose sodium, light anhydrous silicic acid, hydrated silicon dioxide, silicon dioxide, precipitated calcium carbonate, anhydrous calcium hydrogen phosphate, magnesium oxide, titanium oxide, calcium lactate, magnesium aluminometasilicate, synthetic hydrotalcite, talc, and kaolin, etc. These excipients can be used alone or in combination of two or more as ingredients of the present solid preparation. The aforementioned (B) component (starch) also falls under the category of (D) excipient. In this specification, when it is simply stated that a "(D) excipient" or a "(D) component" is used, it means an excipient in general that includes the (B) component, and when it is stated that a "(D) excipient other than starch" or a "(D) component other than starch" is used, it means an excipient other than the (B) component (starch). The (D) excipient can be used as a blending component of the granules during the production of the present solid preparation, and can also be used as an ingredient (extra-granule additive) that is subsequently added to the granules (core granules).

[0036] As the component (D) other than starch, preferred examples include sugar alcohols and sugars. As the component (D) other than starch used as a compounding component of the granulated material, D-mannitol is more preferable. The specific surface area of ​​D-mannitol is not particularly limited as long as it does not interfere with the effects described in this specification. Incidentally, the specific surface area is a value measured by the BET method, and can be measured, for example, using a specific surface area measuring device Macsorb HM-model 1220 (manufactured by Mountec Co., Ltd.).

[0037] Examples of D-mannitol that is commercially available as a pharmaceutical additive include Mannitol C (average particle size: 20 μm), Mannitol P (average particle size: 50 μm), Mannitol S (average particle size: 150 μm) (all from Mitsubishi Corporation Foodtech Co., Ltd.), Pearitol 25C (average particle size: 25 μm), Pearitol 50C (average particle size: 50 μm), Pearitol 160C (average particle size: 160 μm) (all from ROQUETTE), Nonpareil 108 (100) (average particle size: 100 μm), and Nonpareil 108 (200) (average particle size: 200 μm) (all from Freund Corporation).

[0038] The proportion of the (D) component (total amount including the (B) component) contained in the solid preparation is not limited and can be selected from the range of 20 to 99% by mass per 100% by mass of the total amount of the solid preparation, preferably 60 to 99% by mass, more preferably 80 to 99% by mass.

[0039] When the present solid preparation is a tablet produced by the production method A, the proportion of the (D) component contained in the present solid preparation (total amount including the (B) component) is not limited and can be selected from the range of 20 to 99% by mass per 100% by mass of the total amount of the solid preparation. It is preferably 60 to 99% by mass, more preferably 85 to 99% by mass. When the content of the (D) component is converted into the content per 100 parts by mass of the granulated product contained in the tablet, it can be 20 to 99 parts by mass. It is preferably 60 to 99 parts by mass, more preferably 85 to 99 parts by mass. Here, the (D) component can be, in addition to starch, which is the (B) component, preferably D-mannitol.

[0040] When the present solid preparation is a tablet produced by the production method B, the proportion of the (D) component contained in the present solid preparation (total amount including the (B) component) is not limited and can be selected from a range of 20% by mass or more per 100% by mass of the total amount of the solid preparation, preferably 60 to 99% by mass, more preferably 80 to 99% by mass. Among these, the proportion of the (D) component contained in the granules can be 20 to 99 parts by mass, preferably 60 to 99 parts by mass, more preferably 80 to 99 parts by mass per 100 parts by mass of the granules. Here, the (D) component can be, in addition to starch, which is the (B) component, preferably D-mannitol.

[0041] (E) Disintegrant Specific examples of the (E) disintegrant include, but are not limited to, carmellose, carmellose calcium, carmellose sodium, croscarmellose sodium, sodium starch glycolate, crospovidone, cation exchange resins, crystalline cellulose, and low-substituted hydroxypropyl cellulose, etc. These disintegrants can be used alone or in combination of two or more kinds. In addition, the disintegrant (E) can be used as a compounding component of the granules during the production of the present solid preparation, and can also be used as a component (extragranular additive) that is subsequently added to the granules (core granules).

[0042] As the component (E), preferably, low-substituted hydroxypropyl cellulose, crospovidone, and croscarmellose sodium can be mentioned, and as the component (E) used as a compounding component of the granulated product, more preferably, low-substituted hydroxypropyl cellulose and crospovidone.

[0043] The proportion of the component (E) contained in the present solid preparation is not limited and can be selected from the range of 0 to 20% by mass per 100% by mass of the total amount of the solid preparation, preferably 0 to 15% by mass, and more preferably 0 to 10% by mass.

[0044] When the present solid preparation is a tablet produced by the production method A, the proportion of the (E) component contained in the present solid preparation is not limited and can be selected from the range of 0 to 20% by mass per 100% by mass of the total amount of the solid preparation, preferably 0 to 15% by mass, more preferably 0 to 10% by mass, and even more preferably 2 to 7 parts by mass. When the content of the (E) component is converted into the content per 100 parts by mass of the granulated product contained in the tablet, it can be 0 to 20 parts by mass. It is preferably 0 to 15 parts by mass, more preferably 0 to 10 parts by mass, and even more preferably 3 to 8 parts by mass.

[0045] When the present solid preparation is a tablet produced by the production method B, the proportion of the (E) component contained in the present solid preparation is not limited and can be selected from the range of 0 to 20% by mass per 100% by mass of the total amount of the solid preparation, preferably 0 to 15% by mass, and more preferably 0 to 10% by mass. Among these, the proportion of the (E) component contained in the granulated product can be 0 to 20 parts by mass per 100 parts by mass of the granulated product. It is preferably 0 to 15 parts by mass, and more preferably 0 to 10 parts by mass.

[0046] (F) Lubricant Examples of (F) lubricants include, for example, stearic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, talc, waxes, DL-leucine, sodium lauryl sulfate, magnesium lauryl sulfate, macrogol, and light anhydrous silicic acid. These can be used alone or in combination of two or more. Magnesium stearate is preferred.

[0047] (F) Lubricant may be used, without limitation, as an ingredient that is usually added later to the granules (core granules) (an additive outside the granules) during the production of the present solid preparation.

[0048] The proportion of the (F) component contained in the present solid preparation is not limited and can be selected from the range of 0.1 to 10% by mass, preferably 0.2 to 5% by mass, and more preferably 0.2 to 3% by mass, per 100% by mass of the total amount of the solid preparation.

[0049] (G) Any pharmaceutical excipient other than (D) to (F) above Other optional ingredients may include pharmaceutical additives that are typically added to solid preparations, including, without limitation, solubilizers, flow agents, surfactants, pH adjusters, plasticizers, colorants, and flavoring agents.

[0050] Examples of the solubilizing agent include magnesium oxide, calcium oxide, sodium citrate, magnesium chloride, sodium carbonate, and sodium bicarbonate.

[0051] Examples of flow agents include, for example, light anhydrous silicic acid, hydrous silicon dioxide, synthetic aluminum silicate, talc, and magnesium aluminometasilicate.

[0052] Examples of the surfactant include nonionic surfactants and anionic surfactants such as polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene, polyoxyethylene fatty acid esters, glycerin monostearate, sorbitan fatty acid esters (sorbitan monostearate, sorbitan monolaurate, etc.), polysorbates, sodium lauryl sulfate, macrogols, sucrose fatty acid esters, sodium alkyl sulfate, etc.

[0053] Examples of the pH adjuster include glycine, sodium bicarbonate, calcium hydrogen phosphate, sodium hydrogen phosphate, organic acids such as acetic acid, succinic acid, tartaric acid, fumaric acid or citric acid, or salts thereof.

[0054] Examples of plasticizers include, for example, triethyl citrate, polyethylene glycol, triacetin, and cetanol.

[0055] Examples of the coloring agent include titanium oxide, talc, ferric oxide, yellow ferric oxide, food yellow No. 4, and aluminum lake food yellow No. 4, and preferably titanium oxide, ferric oxide, and yellow ferric oxide. The content of the coloring agent is less than 0.1% by weight of the total weight of the solid preparation.

[0056] Examples of flavoring agents include, but are not limited to, sweeteners such as aspartame and stevia, ascorbic acid, menthol, crude licorice extract, and simple syrup; examples of sweetening agents include natural or synthetic sweeteners such as sucrose, D-sorbitol, xylitol, and aspartame; and examples of flavoring agents include menthol and mint.

[0057] (H) Coating layer As described above, the present solid preparation may be an uncoated tablet or a coated tablet (sugar-coated tablet, gelatin-encapsulated tablet, film-coated tablet) having a coating layer (covering layer) on its surface.

[0058] When the present solid preparation is a coated tablet, the coating agent used to form the coating layer can be appropriately selected and used based on the technical common sense of the art depending on the purpose.

[0059] For example, sugars such as sucrose, D-mannitol, erythritol, sorbitol, xylitol, and trehalose are used to prepare sugar-coated tablets. In addition, for the preparation of film-coated tablets, polymer compounds such as water-soluble coating agents such as hydroxypropyl cellulose (HPC), hypromellose, polyvinyl alcohol, and pullulan; enteric coating agents such as hypromellose phthalate (HPMCP), hydroxypropyl methylcellulose acetate succinate (HPMCAS), carboxymethylethylcellulose (CMEC), methacrylic acid copolymer, ceracephate (cellulose acetate phthalate), and shellac; gastric coating agents such as polyvinyl acetal diethylaminoacetate, aminoalkyl methacrylate copolymer, and polyvinyl acetate diethylaminoacetate; and sustained-release coating agents such as ethylcellulose and aminoalkyl methacrylate copolymer are used.

[0060] In addition, these coating agents can be blended with one or more of coloring agents, flavoring agents, sweeteners, fragrances, light-shielding agents, plasticizers, etc., as necessary. The blending ratio of these coloring agents, etc. in the coating layer is not limited, but is appropriately adjusted to be in the range of 0 to 20% by mass relative to the total amount (100% by mass) of the components forming the coating layer.

[0061] In coated tablets, the proportion of the coating layer (coating layer, film) is not limited and can usually be appropriately selected from the range of 1 to 12 parts by mass per 100 parts by mass of the uncoated tablet, preferably 1 to 10 parts by mass, and more preferably 2 to 8 parts by mass.

[0062] (Use of this solid dosage form) Compound I has excellent prostaglandin I2 (also known as PGI2) receptor agonism and is known to exhibit various medicinal effects, such as platelet aggregation inhibition, vasodilatory action, bronchial smooth muscle dilation, lipid deposition inhibition, and leukocyte activation inhibition (Patent Documents 1 to 7).

[0063] Therefore, the present solid preparation is effective in treating diseases in which PGI2 is involved, such as transient ischemic attack (TIA), diabetic neuropathy (see, for example, Non-Patent Document 1), diabetic gangrene (see, for example, Non-Patent Document 1), peripheral circulatory disorders (e.g., chronic arteriosclerosis, chronic arterial occlusion) (see, for example, Non-Patent Document 2), intermittent claudication (see, for example, Non-Patent Document 3), peripheral arterial embolism, Raynaud's disease (see, for example, Non-Patent Document 4, Non-Patent Document 5), collagen diseases (e.g., systemic lupus erythematosus, scleroderma) (see, for example, Patent Document 3, Non-Patent Document 6), mixed connective tissue disease, vascular inflammatory symptoms, and the like. group, reocclusion / restenosis after percutaneous transluminal coronary angioplasty (PTCA), arteriosclerosis, thrombosis (e.g., acute cerebral thrombosis, pulmonary embolism) (see, for example, Non-Patent Document 5 and Non-Patent Document 7), hypertension, pulmonary hypertension such as pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (see, for example, Non-Patent Document 8 and Non-Patent Document 9), ischemic disease (e.g., cerebral infarction, myocardial infarction) (see, for example, Non-Patent Document 10), angina pectoris (e.g., stable angina pectoris, unstable angina pectoris) (see, for example, Non-Patent Document 11), glomerulonephritis (see, for example, Non-Patent Document 12), diabetic nephropathy (see, for example, Non-Patent Document 1), chronic renal failure (see, for example, Patent Document 4), allergies, bronchial asthma (see, for example, Non-Patent Document 13), ulcers, bedsores, restenosis after coronary interventions such as atherectomy and stent placement, thrombocytopenia due to dialysis, diseases involving fibrosis of organs or tissues [for example, kidney diseases (e.g., tubulointerstitial nephritis) (see, for example, Patent Document 3), respiratory diseases (e.g., interstitial pneumonia (pulmonary fibrosis) (see, for example, Patent Document 3), chronic obstructive pulmonary disease (see, for example, Non-Patent Document 14), etc.], digestive diseases (e.g., liver cirrhosis, viral hepatitis, chronic pancreatitis, gastric cancer), cardiovascular disease (e.g., myocardial fibrosis), bone and joint disease (e.g., myelofibrosis, rheumatoid arthritis), skin disease (e.g., postoperative scars, burn scars, keloids, hypertrophic scars), obstetric disease (e.g., uterine fibroids), urological disease (e.g., benign prostatic hyperplasia), other diseases (e.g., Alzheimer's disease, sclerotic peritonitis, type I diabetes, postoperative organ adhesions), erectile dysfunction (e.g., diabetic erectile dysfunction, psychogenic erectile dysfunction, psychotic erectile dysfunction, erectile dysfunction due to chronic renal failure, erectile dysfunction after pelvic surgery for prostate removal, vascular erectile dysfunction due to aging or arteriosclerosis) (e.g.,see Patent Document 7), inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease, intestinal tuberculosis, ischemic colitis, intestinal ulcers associated with Behcet's disease) (see, for example, Patent Document 5), gastritis, gastric ulcer, ischemic eye disease (e.g., retinal artery occlusion, retinal vein occlusion, ischemic optic neuropathy), sudden hearing loss, avascular bone necrosis, nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., diclofenac, meloxicam, oxaprozin, nabumetone, indomethacin, ibuprofen, ketoprofen, naproxen, The solid preparation of the present invention is useful as a preventive or therapeutic agent for intestinal injury (for example, mucosal injury such as erosion or ulcer occurring in the duodenum, small intestine or large intestine, which is not particularly limited as long as it occurs in the duodenum, small intestine or large intestine) associated with administration of celecoxib (see, for example, Patent Document 8), and symptoms (for example, paralysis, hypoesthesia, pain, numbness, decreased walking ability) associated with spinal canal stenosis (for example, cervical spinal canal stenosis, thoracic spinal canal stenosis, lumbar spinal canal stenosis, diffuse spinal canal stenosis, sacral stenosis) (see, for example, Patent Document 6). The solid preparation of the present invention is also useful as a promoter of angiogenesis therapy such as gene therapy or autologous bone marrow cell transplantation, and as an angiogenesis promoter in peripheral vascular reconstruction or angiogenesis therapy.

[0064] (Characteristics of this solid dosage form) The present solid preparation has at least the following characteristics (a) and (b).

[0065] (A) Good disintegrability Specifically, the solid preparation has the following disintegration characteristics: (i) In the case of uncoated tablets Disintegrates within 2 minutes in a disintegration test (without using auxiliary disks) specified by the Japanese Pharmacopoeia using water at 37°C as the test liquid. Here, "disintegrates" can be determined as "disintegrating" when all of the six test tablets disintegrate in one disintegration test, or when one or two do not disintegrate, and then a disintegration test is conducted on 12 more test tablets, and 16 or more of the total 18 test tablets disintegrate. The solid preparation produced by production method A preferably has the property of disintegrating within 1 minute, more preferably within 0.9 minutes, and even more preferably within 0.8 minutes. In the case of a solid preparation produced by production method B, it preferably has the property of disintegrating within 2 minutes, more preferably within 1.8 minutes, and even more preferably within 1.7 minutes. (ii) Coated tablets In the above disintegration test (without using an auxiliary disk), the tablet disintegrates within 2 minutes, preferably within 1.8 minutes, and more preferably within 1.7 minutes.

[0066] (a) Good stability (inhibits the formation of related substances due to the decomposition of Compound I) Specifically, in this solid preparation, the generation of related substances due to the decomposition of component (A) (compound I) that may occur over time is suppressed. The stability can be determined by comparing the content of related substances generated in the solid preparation before and after a storage test. Specifically, the stability can be determined according to the following criteria based on the content of related substances contained in 100% by mass of the solid preparation after the storage test.

[0067] (i) After storage for one month under open conditions at 40°C and 75% RH in the dark, the content of the related substances is 1.5% by mass or less. (ii) After storage at 60° C. in an open, dark place for one month, the content of the related substances is 1.5% by mass or less. In this case, "40°C, 75% RH open conditions" means that the solid preparation is placed in an open container and the specimen is exposed to conditions of 40°C, 75% RH, and "60°C open conditions" means that the solid preparation is placed in an open container and the specimen is exposed to conditions of 60°C. The measurement of the content of related substances in a solid preparation will be described in detail in the Examples section below, but simply, the amount of related substances contained in a solid preparation after storage can be determined by quantifying the amount of related substances using high performance liquid chromatography.

[0068] (Effect of solid preparations) According to this solid preparation, the content of starch per 100 parts by mass of granules containing compound I, starch, and at least one binder selected from the group consisting of hydroxypropylcellulose and hypromellose is 20 parts by mass or more (excluding 30.2 to 30.4 parts by mass), and the content of binder per 100 parts by mass of the granules is 4 parts by mass or less. This makes it possible to shorten the disintegration time of the solid preparation and to suppress the generation of related substances due to the decomposition of compound I in the solid preparation. Therefore, according to this solid preparation, it is possible to suppress the decrease in stability of compound I, which is an active ingredient in the solid preparation, while improving the disintegration property.

[0069] The solid preparation preferably has a tablet form, more preferably a relatively small and small tablet with a total mass of about 20 to 35 mg per tablet. Preferably, the total mass per tablet is 30 mg or less. Examples of such tablets include tablets with a total mass of 18 to 22 mg per tablet, a content of component (A) of 80 to 120 μg per tablet, a diameter of 2.5 to 3.5 mm, and a thickness of 1.5 to 2.5 mm.

[0070] When the present solid preparation is a tablet, its shape is not particularly limited, and includes, for example, tablets having any shape, such as a circle, an oval, or a diamond, when viewed from the front (top), and preferably has a circle as a planar shape.

[0071] When the solid preparation is a tablet, it may be administered once or multiple times (e.g., 2 to 6 times) per day. The dosage per time (single dosage) can be selected according to the sex, age, severity of the disease, etc. For example, in the case of tablets, one tablet or multiple tablets (e.g., 2 to 6 tablets) may be administered per time.

[0072] (II) Manufacturing method of a solid preparation containing selexipag The present solid preparation can be prepared according to a conventional method in the art depending on its shape. A preferred embodiment of the solid formulation is a tablet, in which case the solid formulation can be preferably manufactured using a wet granule compression method.

[0073] A preferred embodiment of the manufacturing method according to the present disclosure (hereinafter also referred to as "this manufacturing method") includes a method in which components (A) and (B) and, if necessary, other components (e.g., components (D) and (E) excluding starch) are mixed in powder form, component (C) prepared in a solution form is added to this, granulated (wet granulation), dried, and then granulated, and component (F) is added and compressed (tableted) to produce the product (this is also referred to in the present specification as "manufacturing method A").

[0074] Furthermore, another preferred embodiment of the manufacturing method according to the present disclosure (the present manufacturing method) includes a method in which components (A) and (B) and, if necessary, other components (e.g., components (D) and (E) excluding starch) are mixed in powder form, component (C) prepared in a solution form is added to the mixture, the mixture is granulated (wet granulation), and after drying and sieving, component (F) and other components (e.g., components (D) and (E)) are blended, and the mixture is compressed and molded (tableted) to produce the product (this is also referred to in the present specification as "manufacturing method B").

[0075] This is described step by step as follows: (1) a step of powder-mixing at least the (A) and (B) components to prepare a powder mixture (mixing step); (2) A step of adding a solution containing component (C) to the powder mixture and granulating the mixture to obtain a granulated product (granulation step); (3) A step of drying and sizing the granulated product as necessary (sizing step); (4) A step of blending an additive outside the granules with the sized granules (core granules) (post-addition step); and (5) A step of compression molding the mixture obtained in the post-addition step (compression molding step).

[0076] When the external additive added in step (4) is component (F), the manufacturing method corresponds to the above-mentioned "manufacturing method A." When the external additive added in step (4) contains other components (e.g., components (D) and (E)) in addition to component (F), the manufacturing method corresponds to the above-mentioned "manufacturing method B."

[0077] The present solid preparation may be an uncoated tablet, but may be coated if necessary. When the present solid preparation is a coated tablet having a coating layer, the coated tablet can be produced by subjecting the tablet (uncoated tablet) obtained in the above step (5) to the coating step (6).

[0078] Each step is briefly described below. (1)Mixing process The powder mixture components used for granulation, such as at least the components (A) and (B) and, if necessary, other optional components, may be previously pulverized with a pulverizer (e.g., a cutter mill, a rotary mill, a hammer mill, a roll mill, a shear mill, a ball mill, or a jet mill) and, if necessary, classified.

[0079] In the mixing step, the (A) and (B) components, and other components as necessary, may be mixed by any method that can uniformly mix the powders of these components, and the mixing method is not particularly limited. An example of the method is, but is not limited to, a method in which the raw materials are fed into a fluidized bed granulation dryer and mixed while being fluidized. Another example is a method in which the raw materials are mixed using a mixer such as a rotary mixer (e.g., a V-type mixer, a double cone mixer), a stationary mixer (a ribbon mixer, a screw mixer), etc.

[0080] The mixing ratio of components (A) and (B) and the blending ratio of other optional components (e.g., component (D) excluding starch) are as described in section (I) above, and the descriptions therein are incorporated herein by reference.

[0081] (2) Granulation process Granulation can be carried out by a method (wet granulation method) in which a solution of the (C) component, preferably an aqueous solution of the (C) component, is added to the powder mixture containing at least the (A) and (B) components prepared above to granulate. The concentration of the aqueous solution of the (C) component used varies depending on the (C) component used, and is not limited, but can usually be appropriately selected from the range of 0.5 to 20% by mass. As described in the above section (I), the blending amount of the (C) component can be adjusted so that the ratio of the (C) component to the total amount of the solid preparation finally produced (100% by mass) is in the range of 0.5 to 4% by mass on a dry weight basis. It is preferably 0.5 to 3.5% by mass. The proportion of component (C) in 100 parts by mass of the granules can be appropriately set and selected depending on the production methods A and B, as described in the above section (I).

[0082] The granulation method may be any wet granulation method commonly used in the technical field, and examples thereof include, without limitation, an extrusion granulation method in which a solution of component (C) is added to a raw powder mixture, kneaded, and the kneaded mixture is extruded through a screen to form granules; a crushing granulation method in which the kneaded mass prepared by the above method is cut with the rotating blade of a granulator and ejected from the outer screw holes by centrifugal force; a tumbling granulation method in which a solution of a binder is added to a raw powder mixture, the humidified powder is subjected to rotational motion or vibration to agglomerate, and nearly spherical particles are obtained; a fluidized bed granulation method in which a raw powder mixture is fluidized from below by a hot air current, and a solution of a binder is sprayed onto it to granulate; and an agitation granulation method in which the raw powder is placed in a container, stirred with a rotating blade, and water or granulation liquid is added to agglomerate the raw powder particles into spherical particles.

[0083] (3) Sizing process The granules prepared in the above step (2) can be dried using a drying method generally used in the art. For example, various drying devices such as a parallel flow box dryer, a through-flow box dryer, a fluidized bed dryer, and a vacuum dryer can be used. In the above box, through-flow, and fluidized bed methods, it is preferable to dry the granules by blowing air (hot air) heated to about 80 to 90°C onto them.

[0084] The sizing method is not particularly limited, and a sizing method generally used in the technical field can be adopted, and is not particularly limited. Preferably, the sizing is performed to a particle size such that there are no coarse particles of 1000 μm or more and the average particle size of the granulated product is in the range of 50 to 400 μm. Here, the "average particle size" refers to the average particle size calculated from the results of the sieving method of the powder particle size measurement method 2 specified in the general test method of the Japanese Pharmacopoeia, 17th Edition.

[0085] (4) Post-addition process This step involves adding and mixing various powdered components (external additives to the granules) (also simply referred to as "post-added components") to the granules prepared in the above-mentioned (3) sizing step.

[0086] In manufacturing method A, component (F) in powder form is added as a component to be added later and mixed in. In manufacturing method B, in addition to component (F) in powder form, other components in powder form (e.g., components (D) and (E)) are mixed in as components to be added later. As with step (1) above, the mixing may be carried out by any method that can uniformly mix the sized granules with the powdered external additives, and can be carried out, for example, by using a mixer such as a rotary mixer or a fixed mixer.

[0087] (5) Compression molding process The compression molding process can be carried out by tableting. Tableting can be carried out by a tableting method generally used in the art. Specifically, it can be carried out using a conventional tableting machine such as a single punch tableting machine or a rotary tableting machine.

[0088] Here, the tableting pressure and other tableting conditions are not limited as long as tablets having the effects of the present invention can be produced, and the following conditions can be mentioned.

[0089] The tableting pressure is usually 9.8 to 784 N / mm 2 However, preferably, the strength is 93 to 694 N / mm 2More preferably, it is 147 to 462 N / mm 2 Alternatively, instead of mixing the component (F) in the post-addition step (4), an external lubrication method may be used in which the component (F) is sprayed onto the punch and die prior to the compression molding step (5), and then the compression molding step (5) is carried out.

[0090] (6) Coating process For coating, a coating method generally used in the art can be adopted, such as a pan coating method, a fluidized bed coating method, and an aerated dry pan coating method, and coating can be performed using a coating device suitable for these methods.

[0091] The coating can be carried out by applying a coating liquid prepared by blending the above-mentioned coating agent with a colorant, a flavoring agent, a sweetener, a fragrance, etc., as necessary, onto the surface of the plain tablet produced in steps (1) to (5).

[0092] The coating is prepared so that the ratio of the coating layer to 100 parts by mass of the uncoated tablet is usually 1 to 12 parts by mass, preferably 1 to 10 parts by mass, and more preferably 2 to 8 parts by mass, in terms of dry weight.

[0093] (Effects of manufacturing method of solid preparations) According to the method for producing a solid preparation of the present invention, the method includes a step of powder-mixing the (A) component and the (B) component (mixing step), and a step of granulating the obtained powder mixture using the (C) component (granulation step). In the mixing step, the powder mixture is prepared so that the content of the (B) component per 100 parts by mass of the granulated product is 20 parts by mass or more (excluding 30.2 to 30.4 parts by mass), and in the granulation step, a solution containing the (C) component is added so that the content of the (C) component per 100 parts by mass of the granulated product is 4 parts by mass or less. This makes it possible to produce a solid preparation that has a short disintegration time and suppresses the generation of related substances due to the decomposition of the (A) component (compound I) in the solid preparation. Therefore, according to the method for producing a solid preparation of the present invention, it is possible to produce a solid preparation that can suppress the decrease in the stability of the compound I in the solid preparation while improving the disintegration property.

[0094] (III) Method for inhibiting decomposition of selexipag in a solid preparation containing selexipag The present invention provides a method for suppressing the decomposition of the component (a) in a solid preparation containing a granulated product containing (a) compound I, (b) starch, and (c) a binder. The method is characterized in that at least one compound selected from the group consisting of HPC and hypromellose is used as the component (c). The granulated product may further contain D-mannitol as an excipient (d) other than starch. In this case, the mass ratio of the component (b) to the component (d) other than starch can be, but is not limited to, in the range of (b) component:(d) component other than starch=10:0 to 2:8.

[0095] Here, (a) compound I, (b) starch, (c) binder, and (d) excipient correspond to those described in the above sections (I) and (II) as component (A), component (B), component (C), and component (D), respectively. Therefore, the types and mixing ratios thereof, as well as the manufacturing method of a solid preparation containing these components, can be referenced to the above descriptions. According to the method of the present invention, in a solid preparation containing a granulated material containing (a) compound I, (b) starch, and (c) a binder, the generation of related substances due to the decomposition of component (a) (compound I) in the solid preparation can be significantly suppressed. In other words, according to the method of the present invention, the decrease in the stability of compound I in the solid preparation can be suppressed.

[0096] (IV) Method for inhibiting the decomposition of selexipag and improving disintegrability in a solid preparation containing selexipag The present invention provides a method for suppressing the decomposition of the (a) component in a solid preparation containing a granulated product containing (a) compound I, (b) a disintegrant, and (c) a binder, and improving disintegrability in an aqueous solution. The method is characterized in that at least one compound selected from the group consisting of HPC and hypromellose is used as the (c) component. The solid preparation to be treated here is preferably a tablet. The granulated product may further contain D-mannitol as an excipient (d) other than starch. In this case, the mass ratio of the (b) component to the (d) component other than starch can be, but is not limited to, in the range of (b) component:(d) component other than starch=10:0 to 2:8.

[0097] Here, (a) compound I, (b) starch, (c) binder, and (d) excipient correspond to those described in the above sections (I) and (II) as component (A), component (B), component (C), and component (D), respectively. Therefore, the types and mixing ratios thereof, as well as the manufacturing method of a solid preparation containing these components, can be referenced to the above descriptions.

[0098] According to the method of the present invention, for a solid preparation containing a granule containing (a) compound I, (b) starch, and (c) a binder, the generation of related substances due to the decomposition of component (a) (compound I) in the solid preparation can be significantly suppressed, and the disintegration property of the solid preparation, particularly tablets, can be improved and the solid preparation can be disintegrated in a short time. In other words, according to the method of the present invention, the disintegration property of the solid preparation can be improved while suppressing the decrease in the stability of compound I in the solid preparation.

[0099] As described above, in this specification, the terms "comprise" and "contain" include the meanings of "consisting of" and "consisting essentially of". EXAMPLES

[0100] In the following, the present invention will be described using experimental examples to aid in understanding the configuration and effects of the present invention. However, the present invention is not limited by these experimental examples. The following experiments were carried out at room temperature (25±5°C) and atmospheric pressure conditions unless otherwise specified. In the following, "%" means "% by mass" and "parts" means "parts by mass" unless otherwise specified.

[0101] The materials used in the following experimental examples are listed in Table 1. [Table 1]

[0102] Test Method The following test methods were used to evaluate the properties of solid preparations (tablets) in the following Experimental Examples 1 to 7.

[0103] (1) Disintegration test The test liquid was water heated to 37°C, and the experiment was conducted according to the general test method [disintegration test method] (without using auxiliary disks) of the 17th edition of the Japanese Pharmacopoeia. If all six test tablets disintegrated in one disintegration test, or if one or two did not disintegrate, a disintegration test was conducted on 12 more test tablets, and if 16 or more of the total 18 test tablets disintegrated, they were judged to "disintegrate."

[0104] (2) Stability testing The solid preparations (tablets) thus produced were left unpackaged for one month under open conditions of 40°C and 75% RH (referred to as "40°C / 75% RH" in the table below) or / and open conditions of 60°C (referred to as "60°C" in the table below) (both in a dark environment). The contents of compound I and related substances in the solid preparations before and after the storage test were measured using high performance liquid chromatography. Here, the "related substance" refers to a substance that corresponds to the peak (main peak) that is mainly detected, other than the peak derived from compound I, among the multiple peaks detected in the HPLC chromatogram when a solid preparation containing compound I is left under the above conditions for one month and then subjected to high performance liquid chromatography.

[0105] The content of compound I and related substances in a solid formulation by HPLC is measured by dissolving the solid formulation in a solvent and subjecting the sample (test sample) to HPLC. The test sample contains the solvent used for dissolution and components other than compound I and related substances (hereinafter referred to as "other components"). For this reason, the other components and solvent contained in the solid formulation are subjected to HPLC under the same conditions as those used for measurement in advance, and the positions of each peak are confirmed. Next, the peaks of the other components and the solvent can be detected by excluding each peak from the HPLC chromatogram obtained for the test sample. For the related substances, the content of the related substances contained in the solid formulation can be calculated from the ratio of the peak area derived from the related substances to the total area of ​​the peaks excluding the solvent peak. On the other hand, the content of compound I was derived based on a standard substance.

[0106] The measurement by high performance liquid chromatography was carried out under conditions that allowed Compound I and related substances to be separated and detected from other components. Specifically, the test sample was subjected to HPLC using a solvent commonly used in HPLC (e.g., acetonitrile, etc.) as the mobile phase, and detection was performed with a UV detector.

[0107] Experimental Example 1 Evaluation of the presence or absence of binder and granulation method Various tablets (plain tablets) (test formulations 1-1 to 1-4) were prepared according to the formulations shown in Table 2, and the effects of the inclusion or absence of a binder (component (B): corn starch) and the method of its addition on the stability of compound I (component (A)) and the disintegration properties of the tablets were evaluated.

[0108] [Table 2]

[0109] (1) Preparation of granulated material (core granules) [mixing, granulation, and sizing] Test sample 1-1 was prepared by putting components (A), (B), (D), and (E) into a fluidized bed granulation dryer (MP-01, Powrex Corporation), mixing, and spraying and adding a 10% aqueous solution of hydroxypropylcellulose, which had been dissolved in water and prepared as component (C), to granulate. The resulting granules were then sized using a screen-type granulator (Comil QC-197S, Powrex Corporation: screen size 991 μm, rotation speed 25 Hz) to prepare a granulated product (core granules). Test sample 1-2 was prepared by mixing the powdered components (C), (A), (B), (D), and (E) for 10 minutes using a container rotary mixer (Bole Container Mixer LM-20, Hiroshima Metal & Machinery Co., Ltd.) to prepare a powder mixture. Test sample 1-3 was prepared by spraying water onto the powder mixture of components (A), (B), (D), and (E) without using component (C) and granulating the mixture. Test sample 1-4 was prepared by mixing only components (A), (B), (D), and (E) without using component (C).

[0110] (2) Preparation of uncoated tablets (mixing with extragranular additives, tableting) The granules (core granules) or powder mixture prepared in (1) above were mixed with the powdered (F) component in a container rotary mixer (Bole Container Mixer LM-20, Hiroshima Metal & Machinery Co., Ltd.) for 10 minutes to prepare granules for tableting. These were then compressed into tablets at a mass of 15 mg / tablet using a rotary tablet press (Kikusui Seisakusho Correct 12HUK: rotation speed 40 rpm) with a circular tablet die with a diameter of 3 mm, under a tableting load of 378 N / mm 2The mixture was compressed into tablets to obtain circular uncoated tablets (Test Preparations 1-1 to 1-4).

[0111] (3) Evaluation of tablet characteristics According to the above-mentioned test method, the disintegration time, the related substance content (%), and the compound I content (%) in the test preparations were measured (all converted to dry matter content) for the test preparations 1-1 to 1-4. The results are shown in Table 3.

[0112] [Table 3]

[0113] As shown in Table 3, in test preparations 1-3 and 1-4, which were produced by the water granulation method or the direct compression method without adding component (C), a significant increase in related substances was observed after one month of storage in the stability test, and a decrease in the content of Compound I was observed. In addition, in test preparation 1-2, which was produced by granulation with the addition of component (C) in powder form, a significant increase in related substances was observed after one month of storage in the stability test, and a decrease in the content of Compound I was observed. From these results, it was confirmed that in order to increase the stability of compound I in a solid formulation (suppressing the decomposition of compound I) and suppress the generation of related substances, it is preferable to add component (C) in the form of a solution in the granulation process of the production of this solid formulation (wet granulation).

[0114] Experimental Example 2: Examination and evaluation of types of binder The effect of the type of binder (component (C)) used for granulation on the stability of compound I (component (A)) in a solid preparation (tablet) and the disintegration property of the tablet was evaluated.

[0115] (1) Preparation of granules (core granules) and uncoated tablets Granules (core granules) were prepared using the components (A) to (E) according to the recipe in Table 4, using the same wet granulation method as in Test Preparation 1-1. Powdered component (F) was added to the granules, and the core granules were compressed with a tableting load of 378 N / mm in the same manner as in Test Preparation 1-1. 2 The mixture was compressed into tablets to obtain uncoated tablets having a circular planar shape (Test Preparations 2-1 to 2-10).

[0116] [Table 4]

[0117] (2) Evaluation of tablet characteristics According to the above-mentioned test method, the disintegration time, the related substance content (%), and the compound I content (%) in the test preparations were measured (all converted to dry matter content) for the test preparations 2-1 to 2-10. The results are shown in Table 5.

[0118] [Table 5]

[0119] As shown in Table 5, when granulation was performed using a binder other than hydroxypropyl cellulose and hypromellose, a significant increase in related substances and a decrease in the content of Compound I were observed after storage for one month in a stability test. From these results, it was confirmed that in order to increase the stability of Compound I in a solid formulation (suppressing the decomposition of Compound I) and suppress the generation of related substances, hydroxypropyl cellulose or hypromellose is preferable as the binder (component (C)) in the granulation process of the present solid formulation production.

[0120] Experimental Example 3: Evaluation of the blending ratio of component (B) and component (D) The effect of the ratio (mixture ratio) of starch (ingredient (B)) and D-mannitol (ingredient (D)) blended into the granules (core granules) on the stability of compound I (ingredient (A)) in a solid formulation (tablet) and on the disintegration properties of the tablets was evaluated.

[0121] (1) Preparation of granules (core granules) and uncoated tablets Granules (core granules) were prepared using the components (A) to (D) according to the recipe in Table 6, using the same wet granulation method as in Test Preparation 1-1. Powdered component (F) was added to the granules, and the core granules were compressed with a tableting load of 378 N / mm in the same manner as in Test Preparation 1-1. 2The mixture was compressed into tablets to obtain uncoated tablets having a circular planar shape (Test Preparations 3-1 to 3-6).

[0122] [Table 6]

[0123] (2) Evaluation of tablet characteristics According to the above-mentioned test method, the disintegration time, the related substance content (%), and the Compound I content (residual rate) (%) (all converted to dry matter content) of the test preparations 3-1 to 3-6 produced were measured. The results are shown in Table 7.

[0124] [Table 7]

[0125] As shown in Table 7, even without using D-mannitol (component (D)) during granulation, it was confirmed that the stability of compound I in the solid preparation was high (decomposition of compound I was suppressed) and the production of related substances was suppressed (test preparation 3-6). The stability of compound I tended to increase by increasing the proportion of component (B) (or the blending ratio of component (B) to component (D) excluding starch) blended in the solid preparation (core granule). From the results of test preparation 3-2, it is considered that a solid preparation with high stability of compound I can be obtained by blending component (B) at a ratio of 15 parts or more, preferably 19 parts or more per 100 parts of granules (core granule) (14% or more, preferably 18% or more in 100% solid preparation). However, even if the blending amount of component (B) was increased, no significant effect on the disintegration property of the solid preparation was observed. On the other hand, the disintegration time tended to be shortened by adding D-mannitol as an excipient (D) in addition to the starch added as component (B).However, it was confirmed that when only D-mannitol was added without adding component (B), the stability of compound I in the solid preparation decreased (progression of decomposition of compound I) and related substances were significantly generated (test preparation 3-1).

[0126] From these findings, it is believed that in this solid formulation, starch (component (B)) mainly contributes to the stability (inhibition of decomposition) of compound I in the solid formulation. For this reason, in order to prepare a solid formulation that combines the stability (inhibition of decomposition) of compound I in the solid formulation and good disintegration properties of the solid formulation, it is believed to be effective to achieve a balance in the blending of component (B) used in the production of the granules (core granules) and component (D) other than starch (especially D-mannitol). Furthermore, a comparison of the results of test formulation 3-3 in Table 7 with test formulation 2-2 shown for reference showed no effect on stability or disintegration properties due to the presence or absence of low-substituted hydroxypropyl cellulose (component (D)) incorporated in the granules.

[0127] Experimental Example 4: Evaluation of the amount of HPC (component (C)) added When hydroxypropyl cellulose (HPC) was used as component (C) in the production of granules (core granules), the effect of the amount of HPC added on the stability of compound I (component (A)) in a solid formulation (tablet) and on the disintegration properties of the tablet was evaluated.

[0128] (1) Preparation of granules (core granules) and uncoated tablets Granules (core granules) were prepared by the same wet granulation method as in Test Preparation 1-1 using components (A) to (E) according to the recipe in Table 8. Powdered component (F) was added to the granules, and the core granules were compressed with a tableting load of 378 N / mm in the same manner as in Test Preparation 1-1. 2 The mixture was compressed into tablets to obtain uncoated tablets having a circular planar shape (Test Preparations 4-1 to 4-5).

[0129] [Table 8]

[0130] (2) Evaluation of tablet characteristics According to the above-mentioned test method, the disintegration time, the related substance content (%), and the compound I content (residual rate) (%) in the test preparations were measured for the test preparations 4-1 to 4-5 produced according to the above-mentioned test method. The results are shown in Table 9.

[0131] [Table 9]

[0132] As shown in Table 9, by reducing the amount of HPC used as component (C) during granulation, the disintegration time was shortened and disintegration property was improved. However, when the ratio to the tablet (plain tablet) was 1% or less (the ratio to the granules was 1.047 parts or less), a significant increase in related substances and a decrease in the compound I content were observed after storage for 1 month in a stability test.

[0133] From this, it is considered that HPC not only acts as a binder during granulation, but also contributes to maintaining or improving the stability of compound I in a solid preparation (suppressing decomposition of compound I). In addition, from the above results, it is considered that by adjusting the amount of HPC added to 2 parts or more, preferably 2 to 4.1 parts, more preferably 2 to 3.1 parts per 100 parts of granules, a solid preparation that combines the stability of compound I in the solid preparation (suppressing decomposition) and good disintegration property of the solid preparation can be prepared.

[0134] Experimental Example 5 Evaluation of the amount of hypromellose (ingredient (C)) added When hypromellose was used as component (C) in the production of granules (core granules), the effect of the amount of hypromellose added on the stability of compound I (component (A)) in a solid preparation (tablet) and on the disintegration properties of the tablet was evaluated.

[0135] (1) Preparation of granules (core granules) and uncoated tablets Granules (core granules) were prepared by the same wet granulation method as in Test Preparation 1-1 using components (A) to (D) according to the recipe shown in Table 10. Powdered component (F) was added to the granules, and the core granules were compressed with a tableting load of 378 N / mm in the same manner as in Test Preparation 1-1. 2 The mixture was compressed into tablets by a process described below to obtain uncoated tablets having a circular planar shape (Test Preparations 5-1 to 5-6).

[0136] [Table 10]

[0137] (2) Evaluation of tablet characteristics According to the above-mentioned test method, the disintegration time, the related substance content (%), and the Compound I content (residual rate) (%) (all converted to dry matter content) of the test preparations 5-1 to 5-6 produced were measured. The results are shown in Table 11.

[0138] [Table 11]

[0139] As shown in Table 11, similar to the results of HPC shown in Experimental Example 4, by reducing the amount of hypromellose used as component (C) during granulation, the disintegration time is shortened and disintegration property is improved, but when the ratio to the tablet (plain tablet) is 1% or less (the ratio to the granules is 1.047 parts or less), the related substances are significantly increased after storage for 1 month in the stability test, and the compound I content is reduced (test preparation 5-3). From this, it is considered that hypromellose not only acts as a binder during granulation, like HPC, but also contributes to maintaining or improving the stability of compound I in solid preparations (suppressing the decomposition of compound I).

[0140] However, even when the amount of hypromellose added to the tablet (plain tablet) is 1% or less (the ratio to the granulated product is 1.047 parts or less), it was confirmed that the stability of Compound I can be improved while maintaining good disintegration by lowering the hypromellose concentration in the aqueous solution used for granulation to 5% or less. It is considered that such an effect can be similarly observed for the HPC shown in the above Experimental Example 4.

[0141] Experimental Example 6 Evaluation of Manufacturing Method B Instead of the manufacturing method A used in Experimental Examples 1 to 5, various tablets (plain tablets) (test formulations 6-1 to 6-4) were manufactured using manufacturing method B according to the recipes shown in Table 12, and the stability of compound I (component (A)) and the disintegration properties of the tablets were evaluated.

[0142] [Table 12]

[0143] (1) Preparation of granulated material (core granules) (mixing, granulation, and sizing) Among the components of the granulated product (core granules) shown in Table 12, components (A), (B), and (D) were placed in a fluidized bed granulation dryer (MP-01, Powrex Corporation), and while mixing, component (C), which had been dissolved in water in advance to prepare a 2.5% aqueous solution, was sprayed and added to granulate. The resulting granules were then sized using a screen-type granulator (Comil QC-197S, Powrex Corporation) to prepare the granulated product (core granules).

[0144] (2) Preparation of uncoated tablets (mixing with extragranular additives, tableting) The granules (core granules) prepared in (1) above and the extragranular additives (components (D), (E), and (F)) were mixed for 10 minutes in a container rotary mixer (Bohle Container Mixer LM-20, Hiroshima Metal & Machinery Co., Ltd.) to prepare granules for tableting. All of the extragranular additives used here were in powder form. Next, this was compressed into granules using a rotary tablet press (Kikusui Seisakusho Correct 12HUK: rotation speed 40 rpm) with a circular tablet die having a diameter of 3 mm, with a tableting load of 378 N / mm 2 The mixture was compressed into tablets to obtain circular plain tablets.

[0145] (3) Evaluation of tablet characteristics According to the above-mentioned test method, the disintegration time, the related substance content (%), and the Compound I content (residual rate) (%) (all converted to dry matter content) of the test preparations 6-1 to 6-4 produced were measured. The results are shown in Table 13.

[0146] [Table 13]

[0147] As shown in Table 13, by using production method B, it was possible to prepare solid preparations that had both stability (suppression of decomposition) and good disintegrability of Compound I in all formulations, without the influence of external additives added to the granules (core granules). In particular, since production method B can further shorten the disintegration time, it is considered possible to increase the proportion of component (B) used during granulation.

[0148] Furthermore, as shown by these results, a solid formulation that combines the stability (inhibition of decomposition) of Compound I with good disintegrability can be prepared by adjusting the proportion of hypromellose in 100% of the solid formulation (uncoated tablet) to 1% (3.3 parts per 100 parts of granules), and therefore the proportion of hypromellose used for granulation is preferably in the range of 0.5 to 4%, preferably 0.5 to 3.5%, per 100% of the solid formulation (uncoated tablet); or in the range of 0.5 to 4 parts, preferably 0.5 to 3.5 parts, per 100 parts of granules.

[0149] Experimental Example 7 Evaluation of coating agents The tablets (plain tablets) produced in Experimental Example 6 (test preparations 6-1 to 6-4) were coated with a coating film, and the stability of Compound I (ingredient (A)) and the disintegration property of the tablets were evaluated.

[0150] (1) Preparation of coated tablets (coating) The uncoated tablets (test preparations 6-1 to 6-4) produced in Experimental Example 6 were coated with a tablet coating machine (POWREX Corporation, ventilation type coating machine DRC650 type, supply air temperature 50-60°C, air volume 4 m 3 / min) was used to spray an aqueous solution (coating liquid) containing hypromellose (64 parts), propylene glycol (13 parts), trehalose hydrate (13 parts), titanium oxide (10 parts), and yellow ferric oxide (trace amount) per 100 parts of coating (calculated as dry matter).

[0151] (2) Evaluation of tablet characteristics According to the above-mentioned test method, the disintegration time, the related substance content (%), and the Compound I content (residual rate) (%) in the test preparations were measured for the test preparations 7-1 to 7-4 produced according to the above-mentioned test method. The results are shown in Table 14.

[0152] [Table 14]

[0153] As shown in Table 14, all formulations (test formulations 7-1 to 7-4) were able to prepare solid formulations that had both stability (inhibition of decomposition) and good disintegrability of Compound I without being affected by the coating film. As with the uncoated tablets, manufacturing method B can shorten the disintegration time, so it is considered possible to increase the proportion of component (C) used during granulation.

Claims

1. (A) 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide, (B) starch; (C) at least one binder selected from the group consisting of hydroxypropyl cellulose and hypromellose; A solid formulation comprising a granule comprising: The ratio of the component (B) per 100 parts by mass of the granules is 36 parts by mass or more, The ratio of the component (C) per 100 parts by mass of the granules is 0.5 to 4 parts by mass, The granules are wet granulated using component (C) in the form of an aqueous solution. The solid formulation.

2. (A) 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide, (B) starch; (C) at least one binder selected from the group consisting of hydroxypropyl cellulose and hypromellose; (D) at least one excipient selected from the group consisting of sugar alcohols and sugars; (F) a lubricant; A solid formulation comprising: The solid preparation is composed of at least a granule and an excipient other than the granule, The granule contains at least the components (A), (B), (C) and (D), The external additive for the granules contains at least the component (F), At least one of the granules and the external additive for the granules contains (E) at least one disintegrant selected from the group consisting of carmellose, carmellose calcium, carmellose sodium, croscarmellose sodium, crystalline cellulose, low-substituted hydroxypropyl cellulose, and crospovidone; The ratio of the component (B) per 100 parts by mass of the granules is 36 parts by mass or more, The ratio of the (C) component per 100 parts by mass of the granules is 0.5 to 4 parts by mass. The solid formulation.

3. The solid formulation according to claim 2, wherein the granule is wet granulated using component (C) in the form of an aqueous solution.

4. The solid formulation according to claim 2 or 3, wherein the (D) excipient is D-mannitol.

5. The solid formulation according to any one of claims 2 to 4, wherein the mass ratio of the component (B) to the component (D) in the granule is such that the proportion of the component (B) is 2 parts by mass or more when the total of the components (B) and (D) is 10 parts by mass.

6. The solid formulation according to any one of claims 2 to 5, wherein the granules further contain (E) a disintegrant.

7. The solid preparation according to any one of claims 2 to 6, which has a tablet shape and is surface-coated with a coating agent.

8. The solid preparation according to any one of claims 2 to 7, which is for treating a symptom associated with at least one disease selected from the group consisting of diabetic neuropathy, diabetic gangrene, peripheral circulatory disorder, chronic arterial occlusion, intermittent claudication, scleroderma, thrombosis, pulmonary hypertension, myocardial infarction, angina pectoris, glomerulonephritis, diabetic nephropathy, chronic renal failure, bronchial asthma, interstitial pneumonia (pulmonary fibrosis), chronic obstructive pulmonary disease, tubulointerstitial nephritis, inflammatory bowel disease, and spinal canal stenosis.

Citation Information

Patent Citations

  • Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide

    WO2017098998A1

  • Heterocyclic compound derivatives and medicines

    WO2002088084A1

  • Fibrosis inhibitor

    WO2009107736A1

  • Therapeutic agent for spinal canal stenosis

    WO2009157396A1

  • Therapeutic agent for intestinal tract injury accompanying administration of a non-steroid Anti-inflammatory agent

    WO2009157397A1